Lieff Cabraser Named to Leadership Position in Generic Drugs Pricing Antitrust Litigation

Lieff Cabraser Named to Leadership Position in Generic Drugs Pricing Antitrust Litigation

Beginning in February 2015, Lieff Cabraser conducted an extensive investigation into dramatic price increases of certain generic drugs. Lieff Cabraser worked alongside economists and industry experts and interviewed industry participants to evaluate possible misconduct. In December of 2016, Lieff Cabraser, with co-counsel, filed the first case alleging price-fixing of levothyroxine, the primary treatment for hypothyroidism, among the most widely prescribed drugs in the world. [Read more…]

Noncompete Clauses Keep Workers Locked In

Noncompete Clauses Keep Workers Locked In

The use of noncompete clauses in employment contracts has grown enormously. Designed to prevent employees from leaving for a competitor, noncompete agreements also work to bind employees to one company, ultimately making it more difficult for them to get ahead. As noted by the New York Times, this reflects “a broad shift in which companies assert ownership over work experience as well as work,” and the paper further notes that employment lawyers see noncompete agreement usage “exploding.” [Read more…]

Final Approval Granted to $225 Million Barr Labs Settlement in Cipro Antitrust Litigation

Final Approval Granted to $225 Million Barr Labs Settlement in Cipro Antitrust Litigation

On April 21, 2017, Judge Ronald L. Styn of the Superior Court of California granted final approval to a $225 million settlement with Barr Laboratories in the Cipro Antitrust litigation. Lieff Cabraser and co-counsel represent California consumers and third party payors in the class action lawsuit charging that Bayer Corporation, Barr Laboratories, and the HMR Defendants colluded to block consumer access to affordable, generic versions of Cipro through a massive $398.1 million payment by Bayer to Barr and other generic drug makers. [Read more…]

Carolinas HealthCare Anti-Competition Lawsuit Allowed to Proceed

Carolinas HealthCare Anti-Competition Lawsuit Allowed to Proceed

As reported by The Charlotte Observer, North Carolina Business Court Judge Michael Robinson has denied the Carolinas HealthCare System’s motion to dismiss a lawsuit accusing the hospital giant of driving up health care costs through illegal efforts to prevent competition. The lawsuit, filed by Lieff Cabraser and co-counsel in September of 2016, accuses CHS of placing improper contract restrictions on insurers forbidding them from guiding customers to lower-cost competing hospitals. [Read more…]

New Measure That Will Reshape Class Action Lawsuits Under Senate Review

New Measure That Will Reshape Class Action Lawsuits Under Senate Review

A new bill seeking to curb enforcement of U.S. class action lawsuits is facing opposition from antitrust groups, including the Committee to Support the Antitrust Laws (COSAL). The measure, H.R. 985 – Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017, is currently under review by the Senate Judiciary Committee after being passed by the House on a 220-201 vote March 9. The bill would add preconditions for class actions and complex litigation cases. [Read more…]

$225 Million Settlement Announced in Cipro Antitrust Litigation

$225 Million Settlement Announced in Cipro Antitrust Litigation

Lieff Cabraser, Zwerling, Schachter & Zwerling, LLP, and the Joseph Saveri Law Firm represent California consumers and third party payors in a class action lawsuit charging that Bayer Corporation, Barr Laboratories, and the HMR Defendants colluded to block consumer access to affordable, generic versions of Cipro through a massive $398.1 million payment by Bayer to Barr and other generic drug makers. [Read more…]

Dean Harvey Comments on Valeant-Kadmon Pharma Antitrust Challenges

Dean Harvey Comments on Valeant-Kadmon Pharma Antitrust Challenges

Reuters has published a compelling analysis of ongoing challenges facing pharmaceutical “rogue” Valeant with a focus on its price-inflated drug Syprine and its relationship with also-beleagured pharma company Kadmon. Among other issues, Valeant has been singled out as a prime offender in the realm of hyper-inflated pharmaceutical drugs, with, Syprine, its life-saving Wilson’s disease liver ailment treatment costing some patients nearly $300,000 for a year’s use (in 2011, Valeant priced the drug at less than $1,000 for 100 capsules, a rate that rose by 2015 to over $21,000 for the same dose). [Read more…]

DOJ and FTC Release Guidance for Human Resource Professionals on How Antitrust Law Applies to Employee Hiring and Compensation

DOJ and FTC Release Guidance for Human Resource Professionals on How Antitrust Law Applies to Employee Hiring and Compensation

In October 2016, the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice issued formal guidance for human resource (HR) professionals and others who are involved in hiring and compensation decisions. As the FTC put it, “HR professionals are often in the best position to ensure their companies’ hiring practices comply with the law and this guidance will help educate and inform them about how the antitrust laws apply to the employment arena.” [Read more…]

Why Drug Prices Skyrocket Despite Market Competition

Pharmacy

The LA Times has published an excellent piece on the skyrocketing costs of U.S. prescription drugs despite marketplace competition. The absence of competition for a good or service traditionally provides fertile ground for cost escalation and price-gouging, classic greedy anticompetitive behavior, but the Times’ article explores the prevalence of continuing drug cost escalations in the U.S. even where competition does exist. [Read more…]

Brendan Glackin Writes Piece on Trial Witness Management for the California Daily Journal

Brendan Glackin on Witness Challenges

Lieff Cabraser partner Brendan Glackin has written an article for the Daily Journal entitled “Once a Witness is On the Stand, Things Can Only Go Wrong” about the challenges attorneys face when their clients take the stand in court. While the dramatic aspects of unexpected reveals are often larger in the criminal context, the piece notes that civil cases can nevertheless present worrisome challenges at the moment when clients are put before a courtroom to face open-ended questions. [Read more…]